Quick Answer
Clearside Biomedical, Inc. reported Total Revenue of $1.66 million for fiscal year 2024.
Clearside Biomedical, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.66M -79.8% |
$8.23M +519.9% |
$1.33M -95.5% |
$29.57M +274.7% |
$7.89M +263.3% |
$2.17M +7143.3% |
| Revenue (ASC 606) | $1.66M -79.8% |
$8.23M +519.9% |
$1.33M -95.5% |
$29.57M +274.7% |
$7.89M +263.3% |
$2.17M +7143.3% |
| Net Income | -$34.35M -5.7% |
-$32.48M +1.4% |
-$32.95M -8862.5% |
$376.0K +102.1% |
-$18.21M +40.8% |
-$30.77M +62.8% |
| Diluted EPS | -$0.47 +11.3% |
-$0.53 +3.6% |
-$0.55 -5600.0% |
$0.01 +102.6% |
-$0.39 | — |
| Total Assets | $25.13M -26.1% |
$34.02M -33.7% |
$51.30M +19.6% |
$42.90M +122.0% |
$19.32M -27.8% |
$26.78M -39.3% |
| Cash and Equivalents | $20.02M -30.8% |
$28.92M -40.1% |
$48.26M +58.6% |
$30.44M +76.1% |
$17.29M -23.5% |
$22.59M +180.9% |
| Long-Term Debt | — | — | — | — | — | $3.82M -59.5% |
| Stockholders Equity | -$38.85M -144.2% |
-$15.91M -250.0% |
$10.61M -72.1% |
$37.98M +333.4% |
$8.76M -21.5% |
$11.16M -52.8% |
| R&D Expense | $18.59M -10.8% |
$20.85M +6.2% |
$19.63M +5.9% |
$18.54M +23.0% |
$15.07M -3.7% |
$15.66M -77.1% |
| Operating Income | -$28.88M -16.3% |
-$24.84M +17.9% |
-$30.28M -4728.9% |
-$627.0K +96.5% |
-$17.93M +40.8% |
-$30.30M +63.5% |
| Shares Outstanding | 76.58M +21.8% |
62.85M +3.6% |
60.64M +1.5% |
59.72M +15.2% |
51.86M +16.8% |
44.41M +38.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $201.0K | -80.6% | -59.1% |
| Revenue (ASC 606) | September 30, 2025 | $201.0K | -80.6% | -59.1% |
| Net Income | September 30, 2025 | -$5.97M | +22.3% | -32.9% |
| Diluted EPS | September 30, 2025 | -$1.14 | +26.0% | -1800.0% |
| Total Assets | September 30, 2025 | $11.64M | -60.1% | -24.1% |
| Cash and Equivalents | September 30, 2025 | $6.80M | -51.0% | -27.5% |
| Long-Term Debt | September 30, 2020 | $385.0K | -91.1% | -22.4% |
| Stockholders Equity | September 30, 2025 | -$53.95M | -55.1% | -10.7% |
| R&D Expense | September 30, 2025 | $2.93M | -28.9% | +85.2% |
| Operating Income | September 30, 2025 | -$7.04M | -18.6% | -97.3% |
| Shares Outstanding | September 30, 2025 | 5.23M | -93.0% | -93.3% |
- Clearside Biomedical, Inc. reported Total Revenue of $1.66 million for fiscal year 2024.
- Clearside Biomedical, Inc. showed a decrease of -79.8% in Total Revenue compared to the prior fiscal year.
- Clearside Biomedical, Inc. reported Revenue (ASC 606) of $1.66 million for fiscal year 2024.
- Clearside Biomedical, Inc. showed a decrease of -79.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Clearside Biomedical, Inc. reported Net Income of -$34.35 million for fiscal year 2024.
- Clearside Biomedical, Inc. showed a decrease of -5.7% in Net Income compared to the prior fiscal year.
- Clearside Biomedical, Inc. reported Diluted EPS of $0.47 per share (loss) for fiscal year 2024.
- Clearside Biomedical, Inc. showed an increase of +11.3% in Diluted EPS compared to the prior fiscal year.
- Clearside Biomedical, Inc. reported Total Assets of $25.13 million for fiscal year 2024.
- Clearside Biomedical, Inc. showed a decrease of -26.1% in Total Assets compared to the prior fiscal year.
- Clearside Biomedical, Inc. reported Cash and Equivalents of $20.02 million for fiscal year 2024.
- Clearside Biomedical, Inc. showed a decrease of -30.8% in Cash and Equivalents compared to the prior fiscal year.
- Clearside Biomedical, Inc. reported Long-Term Debt of $3.82 million for fiscal year 2019.
- Clearside Biomedical, Inc. showed a decrease of -59.5% in Long-Term Debt compared to the prior fiscal year.
- Clearside Biomedical, Inc. reported Stockholders Equity of -$38.85 million for fiscal year 2024.
- Clearside Biomedical, Inc. showed a decrease of -144.2% in Stockholders Equity compared to the prior fiscal year.
- Clearside Biomedical, Inc. reported R&D Expense of $18.59 million for fiscal year 2024.
- Clearside Biomedical, Inc. showed a decrease of -10.8% in R&D Expense compared to the prior fiscal year.
- Clearside Biomedical, Inc. reported Operating Income of -$28.88 million for fiscal year 2024.
- Clearside Biomedical, Inc. showed a decrease of -16.3% in Operating Income compared to the prior fiscal year.
- Clearside Biomedical, Inc. reported Shares Outstanding of 76.58 million shares for fiscal year 2024.
- Clearside Biomedical, Inc. showed an increase of +21.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: